Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma

In the era of personalized medicine, small-molecule inhibitors have become key to targeting many malignancies. Multiple hematologic malignancies are driven by small-molecule pathways that are seemingly ripe for such targeting. In this case report, we present a patient who was treated with a mitogen-...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Sarah, Kuzu, Amirah, Magill, Mike, Hajdenberg, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050040/
https://www.ncbi.nlm.nih.gov/pubmed/35494913
http://dx.doi.org/10.7759/cureus.23627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050040/
https://www.ncbi.nlm.nih.gov/pubmed/35494913
http://dx.doi.org/10.7759/cureus.23627

Ejemplares similares